30 results about "Cancer relapse" patented technology

The present invention provides a method for preparing a reference model for cancer relapse prediction that provides higher resolution grading than Gleason score alone. The method encompasses obtaining from different individuals a plurality of prostate carcinoma tissue samples of known clinical outcome representing different Gleason scores; selecting a set of signature genes having an expression pattern that correlates positively or negatively in a statistically significant manner with the Gleason scores; independently deriving a prediction score that correlates gene expression of each individual signature gene with Gleason score for each signature gene in said plurality of prostate carcinoma tissue samples; deriving a prostate cancer gene expression (GEX) score that correlates gene expression of said set of signature genes with the Gleason score based on the combination of independently derived prediction scores in the plurality of prostate cancer tissue samples; and correlating said GEX score with the clinical outcome for each prostate carcinoma tissue sample. A set of signature genes is provided that encompasses all or a sub-combination of GI_2094528, KIP2, NRG1, NBL1, Prostein, CCNE2, CDC6, FBP1, HOXC6, MKI67, MYBL2, PTTG1, RAMP, UBE2C, Wnt5A, MEMD, AZGP1, CCK, MLCK, PPAP2B, and PROK1. Also provided a methods for predicting the probability of relapse of cancer in an individual and methods for deriving a prostate cancer gene expression (GEX) score for a prostate carcinoma tissue sample obtained from an individual.

The present invention provides a method for preparing a reference model for cancer relapse prediction that provides higher resolution grading than Gleason score alone. The method encompasses obtaining from different individuals a plurality of prostate carcinoma tissue samples of known clinical outcome representing different Gleason scores; selecting a set of signature genes having an expression pattern that correlates positively or negatively in a statistically significant manner with the Gleason scores; independently deriving a prediction score that correlates gene expression of each individual signature gene with Gleason score for each signature gene in said plurality of prostate carcinoma tissue samples; deriving a prostate cancer gene expression (GEX) score that correlates gene expression of said set of signature genes with the Gleason score based on the combination of independently derived prediction scores in the plurality of prostate cancer tissue samples; and correlating said GEX score with the clinical outcome for each prostate carcinoma tissue sample. A set of signature genes is provided that encompasses all or a sub-combination of GI_2094528, KIP2, NRG1, NBL1, Prostein, CCNE2, CDC6, FBP1, HOXC6, MKI67, MYBL2, PTTG1, RAMP, UBE2C, Wnt5A, MEMD, AZGP1, CCK, MLCK, PPAP2B, and PROK1. Also provided a methods for predicting the probability of relapse of cancer in an individual and methods for deriving a prostate cancer gene expression (GEX) score for a prostate carcinoma tissue sample obtained from an individual.

The present invention relates to the use of a CD24 protein for preventing or treating relapse of a cancer in a subject. The present invention also relates to the use of a CD24 protein for reducing cancer stem cell activity.

The invention discloses an implanted cancer relapse real-time monitoring system. The monitoring system comprises an in-vivo implantation assembly and an in-vitro assembly, wherein the in-vivo implantation assembly can convert concentration information of circulating cell-free nucleic acids in a tissue fluid into transmittal digital information and transmit the digital information to the in-vitro assembly in a wireless transmission manner; the in-vitro assembly analyzes the received circulating cell-free nucleic acid information and informs a user of the implanted cancer relapse real-time monitoring system of paying attention to cancer relapse danger in an information display or warning manner. The implanted cancer relapse real-time monitoring system can monitor a molecular marker, circulating cell-free nucleic acids, of cancer relapse / transfer in real time and can detect the cancer relapse danger in an early stage of cancer relapse, so that a patient suffering from cancer relapse can be treated in time.

Methods of determining cancer progression or cancer relapse in a subject at risk for cancer progression or cancer relapse, the methods comprising: obtaining a sample from said subject; measuring the level of VEGFR1+ hematopoietic progenitor cells (HPCs) and / or VEGFR2+ endothelial progenitor cells (EPCs) in said sample; and taking additional samples and conducting additional measurements of HPCs and / or EPCs at one or more later time points. From the measurements, it can be determined whether there is a surge in the level of HPCs and / or EPCs in at least one later measurement, relative to an earlier measurement. A surge in the level of HPCs and / or EPCs indicates increased risk of progression or relapse of said subject's cancer.

The present invention provides methods and compositions for enhancing efficacy of anti-hormone treatment, or for preventing cancer relapse or progression following treatment. The invention also provides methods for re-sensitizing or sensitizing treatment resistant cancer cells or patients with treatment-refractory cancer cells to continuing or starting anti-hormone treatment. Further provided in the invention are methods for prognosis or diagnosis of anti-hormone treatment effect or likelihood of cancer relapse or metastasis following anti-hormone treatment.

The invention relates to a method for detecting hsa_circ_0007986 as a novel biomarker in serum of a patient with esophageal cancer. The method mainly comprises digital PCR detection of the biomarker shown as SEQ ID NO:1. Primers used in digital PCR amplification comprise a forward primer shown as SEQ ID NO:2 and a reverse primer shown as SEQ ID NO:3. Hsa_circ_0007986 can be used for preparing a diagnosis reagent and / or drug for esophageal cancer. The method for detecting the esophageal cancer is safe and noninvasive, and even asymptomatic population has high acceptability for the detection; hsa_circ_0007986 is high in accuracy and has higher sensitivity and specificity for the esophageal cancer, is suitable for early screening of the esophageal cancer and serving as the biomarker for prognosis of the esophageal cancer, and cancer relapse and treatment effect are monitored.

The present invention relates to methods and compositions for diagnosing prostate cancer and / or determining whether a prostate cancer patient is at increased risk of suffering a relapse, or a rapid relapse, of his cancer. It is based, at least in part, on the results of a comprehensive genome analysis on 241 prostate cancer samples (104 prostate cancer, 85 matched bloods, 49 matched benign prostate tissues adjacent to cancer, and 3 cell lines) which indicate that (i) genome copy number variation (CNV) occurred in both cancer and non-cancer tissues, and (ii) CNV predicts prostate cancer progression.

The present invention pertains to a method of treating cancer or its relapse in mammals by employing platinum based compounds. More particularly, the present invention provides to enhance immunity ina mammal, using a compound of formula I and / or formula II, preferably compound 1 or its derivative, salt, tautomeric form, isomer, polymorph, solvate, or intermediates thereof. The method of inducingan immune response in a mammal is mediated through immune memory. The present invention also provides for such platinum based compounds and their use in treating cancer, metastasis or cancer relapse.